Xingjie Wu

机构：Shenyang Pharmaceutical University, Guiyang Medical University, State Administration of Traditional Chinese Medicine of the People's Republic of China, Affiliated Hospital of Guizhou Medical University, Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences · ORCID：0000-0002-8768-5633

发表论文 69 篇 · 总被引 1154 次 · h-index 16

代表论文

• Dextran-engineered Cu-MOF nanozyme with multi-enzyme mimetic cascade for cuproptosis-enhanced synergistic therapy in triple-negative breast cancer (2025 · International Journal of Biological Macromolecules · 被引 16)
• Magnetic augmentation through multi-gradient coupling enables direct and programmable profiling of circulating biomarkers (2024 · Nature Communications · 被引 15)
• A Nanoplatform Targeting Cascade Pathways for Enhanced Triptolide Delivery in Acute Kidney Injury Therapy (2025 · Advanced Healthcare Materials · 被引 12)
• Polysialic acid driving cardiovascular targeting co-delivery 1,8-cineole and miR-126 to synergistically alleviate lipopolysaccharide-induced acute cardiovascular injury (2024 · International Journal of Biological Macromolecules · 被引 9)
• Aptamer biorecognition and gold nanoshell-mediated fluorescence quenching for glycoprotein analysis and breast cancer diagnosis (2024 · Microchemical Journal · 被引 8)
• One-to-One Fusion-Mediated Single Extracellular Vesicle Analysis for Early Screening of Breast Cancer (2025 · ACS Sensors · 被引 5)